Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date24 Nov 2021 |
坤怡宁颗粒治疗更年期综合征(肾阴阳两虚证)评价其有效性和安全性的随机、双盲、安慰剂对照、多中心临床试验
[Translation] A randomized, double-blind, placebo-controlled, multicenter clinical trial to evaluate the efficacy and safety of Kunyining granules in the treatment of menopausal syndrome (deficiency of both kidney yin and yang syndrome)
进一步评价坤怡宁颗粒治疗更年期综合征(肾阴阳两虚证)的有效性和安全性。
[Translation] To further evaluate the efficacy and safety of Kunyining Granules in the treatment of menopausal syndrome (deficiency of both kidney yin and yang syndrome).
坤怡宁颗粒治疗围绝经期综合征(肾阴阳两虚证)随机、双盲单模拟、安慰剂平行对照、多中心Ⅱ期临床试验
[Translation] A randomized, double-blind, single-dummy, placebo-controlled, multicenter phase II clinical trial of Kunyining granules in the treatment of perimenopausal syndrome (kidney yin and yang deficiency syndrome)
初步评价坤怡宁颗粒治疗围绝经期综合征(肾阴阳两虚证)的有效性和安全性,为Ⅲ期临床试验提供用药依据。
[Translation] To preliminarily evaluate the efficacy and safety of Kunyining Granules in the treatment of perimenopausal syndrome (kidney yin and yang deficiency syndrome) and provide a basis for medication for Phase III clinical trials.
100 Clinical Results associated with Zhejiang Institute of Traditional Chinese Medicine Co., Ltd.
0 Patents (Medical) associated with Zhejiang Institute of Traditional Chinese Medicine Co., Ltd.
100 Deals associated with Zhejiang Institute of Traditional Chinese Medicine Co., Ltd.
100 Translational Medicine associated with Zhejiang Institute of Traditional Chinese Medicine Co., Ltd.